Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in XXXX : a Gynecologic Oncology Group Study.

@entity1 @entity43 @entity137 @entity41 @entity5 @entity843 @entity391 @entity490 @entity221 @entity298
Fourteen @entity1 with persistent @entity43 documented at second look laparotomy after combination chemotherapy were treated with 146 cycles of alpha-recombinant interferon (rIFN-alpha 2) administered i.p. The initial dose was 5 X 10(6) units which was escalated weekly to 50 X 10(6) units over 4 weeks and then continued weekly for a total of 16 weeks. Eleven @entity1 underwent surgical reevaluation after therapy which confirmed four pathological complete responses (36%), one partial response (9%), and disease progression in six @entity1 (55%). Five of seven @entity1 (71%) with @entity41 less than 5 mm had a surgically documented response, whereas there was no response in the four @entity1 whose @entity5 were greater than or equal to 5 mm. Three @entity1 were evaluable for clinical response only: one @entity1 who refused surgery had a complete clinical response with total resolution of @entity843 ; one had stable disease; and one had disease progression. Fever greater than or equal to 38 degrees C was seen in 58%, @entity221 greater than or equal to 39.0 degrees C was seen in 18%, @entity391 in 37%, @entity490 was reported in 22%, and one @entity1 had @entity298 . Peripheral white blood cell counts and i.p. washings were obtained pretreatment and on days 1, 3, and 7 after treatment. While there was no consistent alteration in peripheral white blood cell counts, the numbers of i.p. monocytes and lymphocytes showed a significant boost on day 1 after each dose of rIFN-alpha 2. Natural killer lymphocyte @entity137 was elevated in the i.p. cavity fluid obtained from most @entity1 on day 1 after treatment, while blood natural killer lymphocyte @entity137 values showed considerable variability. Pharmacokinetic studies show that i.p. levels of rIFN-alpha 2 were 30-1000 times blood levels. rIFN-alpha 2 i.p. may act by increasing concentrations of drug and augmenting regional host cells in @entity1 with @entity43 .
